122 related articles for article (PubMed ID: 19684627)
21. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287
[TBL] [Abstract][Full Text] [Related]
22. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J
Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
[TBL] [Abstract][Full Text] [Related]
23. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction.
Kikuta A; Ito M; Mochizuki K; Akaihata M; Nemoto K; Sano H; Ohto H
Bone Marrow Transplant; 2006 Nov; 38(10):665-9. PubMed ID: 17013427
[TBL] [Abstract][Full Text] [Related]
24. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
[TBL] [Abstract][Full Text] [Related]
25. Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options - a Retrospective Analysis.
Wolska-Kuśnierz B; Gregorek H; Chrzanowska K; Piątosa B; Pietrucha B; Heropolitańska-Pliszka E; Pac M; Klaudel-Dreszler M; Kostyuchenko L; Pasic S; Marodi L; Belohradsky BH; Čižnár P; Shcherbina A; Kilic SS; Baumann U; Seidel MG; Gennery AR; Syczewska M; Mikołuć B; Kałwak K; Styczyński J; Pieczonka A; Drabko K; Wakulińska A; Gathmann B; Albert MH; Skarżyńska U; Bernatowska E;
J Clin Immunol; 2015 Aug; 35(6):538-49. PubMed ID: 26271390
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
27. T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Hentschke P; Omazic B; Mattsson J; Näsman-Björk I; Lundkvist I; Gigliotti D; Barkholt L; Ringdén O; Remberger M
Scand J Immunol; 2005 Mar; 61(3):285-94. PubMed ID: 15787747
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
29. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience.
Farzin A; Davies SM; Smith FO; Filipovich A; Hansen M; Auerbach AD; Harris RE
Br J Haematol; 2007 Feb; 136(4):633-40. PubMed ID: 17367413
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience.
Tomizawa D; Imai K; Ito S; Kajiwara M; Minegishi Y; Nagasawa M; Morio T; Nonoyama S; Mizutani S
Am J Hematol; 2004 May; 76(1):33-9. PubMed ID: 15114594
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
33. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections.
Renella R; Picard C; Neven B; Ouachée-Chardin M; Casanova JL; Le Deist F; Cavazzana-Calvo M; Blanche S; Fischer A
Br J Haematol; 2006 Sep; 134(5):510-6. PubMed ID: 16848795
[TBL] [Abstract][Full Text] [Related]
34. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen.
Tolar J; Bonfim C; Grewal S; Orchard P
Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207
[TBL] [Abstract][Full Text] [Related]
35. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism.
Svenberg P; Mattsson J; Ringdén O; Uzunel M
Bone Marrow Transplant; 2009 Dec; 44(11):757-63. PubMed ID: 19421178
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register.
Ferry C; Ouachée M; Leblanc T; Michel G; Notz-Carrére A; Tabrizi R; Flood T; Lutz P; Fischer A; Gluckman E; Donadieu J
Bone Marrow Transplant; 2005 Jan; 35(1):45-50. PubMed ID: 15489867
[TBL] [Abstract][Full Text] [Related]
38. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
40. HSCT for Fanconi anemia in children: factors that influence early and late results.
Dalle JH
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S51-3. PubMed ID: 18978745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
